Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Актуальные вопросы использования комбинированных оральных контрацептивов
Актуальные вопросы использования комбинированных оральных контрацептивов
Дубровина С.О. Актуальные вопросы использования комбинированных оральных контрацептивов. Гинекология. 2018; 20 (2): 60–63.
DOI: 10.26442/2079-5696_2018.2.60-63
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье изложены актуальные вопросы применения комбинированных оральных контрацептивов (КОК): при ожирении, предменструальном синдроме; рассматриваются риск тромбозов при применении КОК и экономическое обоснование скрининга тромбофилии перед назначением КОК, а также «быстрый старт» приема КОК после экстренной контрацепции.
Ключевые слова: комбинированные оральные контрацептивы, ожирение, тромбозы, предменструальный синдром, экстренная контрацепция.
Key words: combined oral contraceptives, obesity, thromboses, premenstrual syndrome, emergency contraception.
Ключевые слова: комбинированные оральные контрацептивы, ожирение, тромбозы, предменструальный синдром, экстренная контрацепция.
________________________________________________
Key words: combined oral contraceptives, obesity, thromboses, premenstrual syndrome, emergency contraception.
Полный текст
Список литературы
1. Rocha ALL, Campos RR, Miranda MMS et al. Safety of hormonal contraception for obese women. Expert Opin Drug Saf 2017; 16 (12): 1387–93.
2. Coney P, Washenik K, Langley RG et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297–302.
3. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–5.
4. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9: CD003987.
5. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
6. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012; 344: e2990. DOI: 10.1136/bmj.e2990
7. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139 (2): 289–96.
8. World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890. DOI: 10.1136/bmj.b2890
10. De Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
11. Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28: 156–63.
12. Edelman AB, Carlson NE, Cherala G et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80: 119–27.
13. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014; 57: 635–43.
14. McNicholas C, Zhao Q, Secura G et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121 (3): 585–92.
15. Sheikh Н, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review headache. Headache 2018; 58 (1): 5–21.
16. Peragallo Urrutia R, Coeytaux RR, McBroom AJ et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013; 122 (2): 380–9.
17. Vernon Е, Hiedemann В, Bowie В. Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical. Appl Health Econ Health Policy 2017; 15 (5): 583–95.
18. Moschos M, Nitoda E. The impact of combined oral contraceptives on ocular tissues: a review of ocular effects. Int J Ophthalmol 2017; 10 (10): 1604–10.
19. Wichianpitaya J, Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int 2013; 2013: 487143.
20. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74 (2): 100–3.
21. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012; 8: CD001324.
22. Faculty of Sexual & Reproductive Healthcare (FSRH). Quick Starting Contraception, 2010. http://www.fsrh.org/documents/ ceuguidancequickstartingcontraception/ (accessed 14 Mar 2017
23. Gemzell-Danielsson K, Berger C, Lalitkumar PGLL. Emergency contraception – mechanisms of action. Contraception 2013; 87: 300–8.
24. Brache V, Cochon L, Duijkers IJ et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015; 30: 2785–93.
25. Cameron ST, Berger C, Michie L et al. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015; 30 (7): 1566–72.
26. Dragoman MV, Tepper NK, Fu R et.al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018. DOI: 10.1002/ijgo.12455 [Epub ahead of print]
27. Aubeny E et al. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004; 9: 267–77.
28. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (5): 397–404. DOI: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12.
29. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Либера. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Libera. [in Russian]
30. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Тренд. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Trend. [in Russian]
31. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Про. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Pro. [in Russian]
32. Von Eickstedt K-W. Sex hormones and related compounds including hormonal contraceptives. Chapter 42 in: MNG Dukes, L Beeley, (eds). Side Effects of Drugs Annual 14, Amsterdam: Elsevier, 1990; p. 349.
33. Denmark. Ministry of Health. Approval of a new oral contraceptive, 1988. Annu Rev Popul Law 1988; 15: 16.
34. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992; 46 (5): 477–88.
35. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3 (4): 179–89.
2. Coney P, Washenik K, Langley RG et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297–302.
3. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–5.
4. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9: CD003987.
5. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
6. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012; 344: e2990. DOI: 10.1136/bmj.e2990
7. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139 (2): 289–96.
8. World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890. DOI: 10.1136/bmj.b2890
10. De Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
11. Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28: 156–63.
12. Edelman AB, Carlson NE, Cherala G et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80: 119–27.
13. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014; 57: 635–43.
14. McNicholas C, Zhao Q, Secura G et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121 (3): 585–92.
15. Sheikh Н, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review headache. Headache 2018; 58 (1): 5–21.
16. Peragallo Urrutia R, Coeytaux RR, McBroom AJ et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013; 122 (2): 380–9.
17. Vernon Е, Hiedemann В, Bowie В. Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical. Appl Health Econ Health Policy 2017; 15 (5): 583–95.
18. Moschos M, Nitoda E. The impact of combined oral contraceptives on ocular tissues: a review of ocular effects. Int J Ophthalmol 2017; 10 (10): 1604–10.
19. Wichianpitaya J, Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int 2013; 2013: 487143.
20. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74 (2): 100–3.
21. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012; 8: CD001324.
22. Faculty of Sexual & Reproductive Healthcare (FSRH). Quick Starting Contraception, 2010. http://www.fsrh.org/documents/ ceuguidancequickstartingcontraception/ (accessed 14 Mar 2017
23. Gemzell-Danielsson K, Berger C, Lalitkumar PGLL. Emergency contraception – mechanisms of action. Contraception 2013; 87: 300–8.
24. Brache V, Cochon L, Duijkers IJ et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015; 30: 2785–93.
25. Cameron ST, Berger C, Michie L et al. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015; 30 (7): 1566–72.
26. Dragoman MV, Tepper NK, Fu R et.al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018. DOI: 10.1002/ijgo.12455 [Epub ahead of print]
27. Aubeny E et al. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004; 9: 267–77.
28. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (5): 397–404. DOI: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12.
29. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Libera. [in Russian]
30. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Trend. [in Russian]
31. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Pro. [in Russian]
32. Von Eickstedt K-W. Sex hormones and related compounds including hormonal contraceptives. Chapter 42 in: MNG Dukes, L Beeley, (eds). Side Effects of Drugs Annual 14, Amsterdam: Elsevier, 1990; p. 349.
33. Denmark. Ministry of Health. Approval of a new oral contraceptive, 1988. Annu Rev Popul Law 1988; 15: 16.
34. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992; 46 (5): 477–88.
35. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3 (4): 179–89.
2. Coney P, Washenik K, Langley RG et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297–302.
3. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–5.
4. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9: CD003987.
5. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
6. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012; 344: e2990. DOI: 10.1136/bmj.e2990
7. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139 (2): 289–96.
8. World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890. DOI: 10.1136/bmj.b2890
10. De Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
11. Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28: 156–63.
12. Edelman AB, Carlson NE, Cherala G et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80: 119–27.
13. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014; 57: 635–43.
14. McNicholas C, Zhao Q, Secura G et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121 (3): 585–92.
15. Sheikh Н, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review headache. Headache 2018; 58 (1): 5–21.
16. Peragallo Urrutia R, Coeytaux RR, McBroom AJ et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013; 122 (2): 380–9.
17. Vernon Е, Hiedemann В, Bowie В. Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical. Appl Health Econ Health Policy 2017; 15 (5): 583–95.
18. Moschos M, Nitoda E. The impact of combined oral contraceptives on ocular tissues: a review of ocular effects. Int J Ophthalmol 2017; 10 (10): 1604–10.
19. Wichianpitaya J, Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int 2013; 2013: 487143.
20. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74 (2): 100–3.
21. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012; 8: CD001324.
22. Faculty of Sexual & Reproductive Healthcare (FSRH). Quick Starting Contraception, 2010. http://www.fsrh.org/documents/ ceuguidancequickstartingcontraception/ (accessed 14 Mar 2017
23. Gemzell-Danielsson K, Berger C, Lalitkumar PGLL. Emergency contraception – mechanisms of action. Contraception 2013; 87: 300–8.
24. Brache V, Cochon L, Duijkers IJ et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015; 30: 2785–93.
25. Cameron ST, Berger C, Michie L et al. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015; 30 (7): 1566–72.
26. Dragoman MV, Tepper NK, Fu R et.al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018. DOI: 10.1002/ijgo.12455 [Epub ahead of print]
27. Aubeny E et al. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004; 9: 267–77.
28. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (5): 397–404. DOI: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12.
29. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Либера. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Libera. [in Russian]
30. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Тренд. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Trend. [in Russian]
31. Инструкция по применению лекарственного препарата для медицинского применения Модэлль Про. / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Pro. [in Russian]
32. Von Eickstedt K-W. Sex hormones and related compounds including hormonal contraceptives. Chapter 42 in: MNG Dukes, L Beeley, (eds). Side Effects of Drugs Annual 14, Amsterdam: Elsevier, 1990; p. 349.
33. Denmark. Ministry of Health. Approval of a new oral contraceptive, 1988. Annu Rev Popul Law 1988; 15: 16.
34. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992; 46 (5): 477–88.
35. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3 (4): 179–89.
________________________________________________
2. Coney P, Washenik K, Langley RG et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297–302.
3. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–5.
4. Gallo MF, Lopez LM, Grimes DA et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9: CD003987.
5. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
6. Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ 2012; 344: e2990. DOI: 10.1136/bmj.e2990
7. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139 (2): 289–96.
8. World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization Copyright (c) World Health Organization 2015.
9. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890. DOI: 10.1136/bmj.b2890
10. De Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
11. Murthy AS. Obesity and contraception: emerging issues. Semin Reprod Med 2010; 28: 156–63.
12. Edelman AB, Carlson NE, Cherala G et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80: 119–27.
13. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014; 57: 635–43.
14. McNicholas C, Zhao Q, Secura G et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121 (3): 585–92.
15. Sheikh Н, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a systematic review headache. Headache 2018; 58 (1): 5–21.
16. Peragallo Urrutia R, Coeytaux RR, McBroom AJ et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013; 122 (2): 380–9.
17. Vernon Е, Hiedemann В, Bowie В. Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical. Appl Health Econ Health Policy 2017; 15 (5): 583–95.
18. Moschos M, Nitoda E. The impact of combined oral contraceptives on ocular tissues: a review of ocular effects. Int J Ophthalmol 2017; 10 (10): 1604–10.
19. Wichianpitaya J, Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int 2013; 2013: 487143.
20. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74 (2): 100–3.
21. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012; 8: CD001324.
22. Faculty of Sexual & Reproductive Healthcare (FSRH). Quick Starting Contraception, 2010. http://www.fsrh.org/documents/ ceuguidancequickstartingcontraception/ (accessed 14 Mar 2017
23. Gemzell-Danielsson K, Berger C, Lalitkumar PGLL. Emergency contraception – mechanisms of action. Contraception 2013; 87: 300–8.
24. Brache V, Cochon L, Duijkers IJ et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015; 30: 2785–93.
25. Cameron ST, Berger C, Michie L et al. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015; 30 (7): 1566–72.
26. Dragoman MV, Tepper NK, Fu R et.al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet 2018. DOI: 10.1002/ijgo.12455 [Epub ahead of print]
27. Aubeny E et al. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004; 9: 267–77.
28. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83 (5): 397–404. DOI: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12.
29. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Libera. [in Russian]
30. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Trend. [in Russian]
31. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Modell' Pro. [in Russian]
32. Von Eickstedt K-W. Sex hormones and related compounds including hormonal contraceptives. Chapter 42 in: MNG Dukes, L Beeley, (eds). Side Effects of Drugs Annual 14, Amsterdam: Elsevier, 1990; p. 349.
33. Denmark. Ministry of Health. Approval of a new oral contraceptive, 1988. Annu Rev Popul Law 1988; 15: 16.
34. Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992; 46 (5): 477–88.
35. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3 (4): 179–89.
Авторы
С.О.Дубровина*
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России. 344022, Россия, Ростов-на-Дону, пер. Нахичеванский, д. 29
*s.dubrovina@gmail.com
Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29
*s.dubrovina@gmail.com
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России. 344022, Россия, Ростов-на-Дону, пер. Нахичеванский, д. 29
*s.dubrovina@gmail.com
________________________________________________
Rostov State Medical University of the Ministry of Health of the Russian Federation. 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29
*s.dubrovina@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.